Osiris shares climb on stem-cell therapy approval

Shares of Osiris Therapeutics traded higher Friday, a day after Canadian regulators approved the company's first-of-a-kind stem cell therapy Prochymal, a treatment for a deadly side effect of bone marrow transplants.

Read more:

Osiris shares climb on stem-cell therapy approval

Related Posts

Comments are closed.